A network of family medicine clinics serve Toronto’s inner-city community

Dr. Karen Weyman, Chief of St. Michael’s Hospital Department of Family and Community Medicine, says the hospital provides a sense of connection, particularly for people feeling socially isolated or facing challenges. “We take an equity lens to everything we do, so that each person gets the care they need.”

Thomas Bollmann

What started in the basement of St. Michael’s Hospital in downtown Toronto nearly 50 years ago has evolved into a network of family medicine clinics. Today, six clinics, located in diverse neighbourhoods in downtown east Toronto, serve the needs of more than 50,000 patients, of whom 30 per cent are living with low income.

Dr. Karen Weyman is Chief of St. Michael’s Hospital Department of Family and Community Medicine (DFCM), which operates the clinics. She says that each location provides comprehensive care, along with various specialties like addiction medicine, HIV and LGBTQ2S+ health – but all have a guiding principle in common.

“We focus on looking after all our patients, with compassion and respect,” she says. “We take an equity lens to everything we do, so that each person gets the care they need.”

Story continues below advertisement

The clinics’ staff of 250, including 80 family physicians and seven nurse practitioners, do that by taking social determinants, like housing, race and income, into account.

For instance, those who can’t afford it have access to physiotherapy, chiropractic, counselling, dental care and legal services. And for those who are having trouble making ends meet, there are staff, known as income support health promoters, who help them negotiate the system.

The department’s work has been so innovative that it was recognized by the World Health Organization for improving primary-care delivery in Toronto’s inner-city community.

For the last eight months, COVID-19 has had a big impact on how care has been provided, according to Dr. Weyman.

“While COVID has affected everyone, it has had a disproportionate impact on people experiencing disadvantage, not only income-wise, but also those living with mental-health conditions, substance-use disorders and HIV,” she notes. “Patients living on lower incomes must go to work and travel to work, putting them at higher risk. And for families living in small spaces, being able to isolate if they need to is difficult.”

COVID-19 has magnified pre-existing challenges of caring for people living in poverty, those experiencing homelesssness or those who face racism, says Dr. Weyman.

“As a society, we can’t ignore social and structural issues that impact people’s health,” she notes. “For instance, patients who don’t have a phone or internet are having more trouble accessing health care.”

Story continues below advertisement

To bridge the gap, within two weeks of the pandemic being declared, St. Michael’s DFCM created a COVID-19 Social Determinants of Health working group. A number of initiatives were launched, including proactive wellness checks for more than 2,000 patients who were especially vulnerable to the effects of COVID-19, providing food cards, referrals to other forms of support and even buying tablets and phones for patients for telemedicine appointments.

“Our health-care team

Read more

Women’s Sexual Medicine Expert, Dr. Adrienne Lara, Joins Exclusive Haute Beauty Network

Dr. Adrienne Lara joins exclusive Haute Beauty Network as a Women’s Sexual Medicine expert representing the Los Angeles market.

OXNARD, Calif. (PRWEB) December 01, 2020

At Celebrating Women Center in Oxnard, California, Dr. Adrienne Lara, MD, wants her patients to know that she went to medical school for you. She believes good patient care is collaborative and involves both the patient and doctor working together as a team to get to the same goal — patient wellness. Dr. Lara takes the time to listen to her patients to better understand who they are, so she’s not treating symptoms, but the whole patient, including their mind, body, and spirit.

Voted favorite MedSpa by the Ventura County Reporter and Best Med Spa Readers’ Choice County Star 2018, Celebrating Women Center offers a number of health and wellness treatments focused on regenerative medicine that allows patients’ natural beauty to shine through, including micro-needling, platelet-rich plasma (PRP), and vaginal rejuvenation with advanced medical treatments such as laser therapy and surgical procedures.

After beginning her career in health care as a nurse, Dr. Lara then went to medical school at Boston University School of Medicine and completed her internship and residency program in obstetrics and gynecology at Beth Israel Deaconess Medical Center, which is part of Harvard Medical School.

Dr. Lara takes great pride in her community and believes as a doctor it’s her role to teach and share her knowledge so that her patients understand that they have options. Her integrity and authenticity when it comes to health care are why she’s so loved by all who see her.

Dr. Lara is fluent in English and Spanish to serve patients from a variety of backgrounds.

Learn more about Dr. Adrienne Lara by visiting: https://hauteliving.com/hautebeauty/member/dr-adrienne-lara/

ABOUT HAUTE BEAUTY NETWORK:

Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.

For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/

For the original version on PRWeb visit: https://www.prweb.com/releases/women_s_sexual_medicine_expert_dr_adrienne_lara_joins_exclusive_haute_beauty_network/prweb17528982.htm

Source Article

Read more

Diaceutics Launches World’s First Diagnostic Network for Precision Medicine to Solve Global Cancer Testing Issues

Diaceutics today launches world’s first digital platform solution to broken testing ecosystem DXRX – The Diagnostic Network®

Global pharma companies, labs and diagnostic companies are leveraging the platform with 38 laboratories and diagnostic companies onboarded and two pharma companies piloting the platform

DXRX provides access to pipeline of global diagnostic testing data on one secure platform and enables industry-wide collaboration to accelerate biomarker test adoption and time to peak therapy prescription from years to months

Early collaborations are now live on DXRX to address real-world cancer testing issues such as PD-L1 reimbursement in the US, and EQA Provision for NGS testing in EU and Asia

Diaceutics PLC, (AIM: DXRX), today announces the launch of DXRX – The Diagnostic Network® which has been designed to accelerate the end-to-end development and commercialization of precision medicine diagnostics by reducing time to peak biomarker test adoption for cancer testing from years to months. As a solution to today’s broken testing ecosystem, DXRX brings together stakeholders from across the industry to collaborate in a vibrant marketplace to solve real-world testing issues in a secure, standardized way for patients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005588/en/

Sarah Colgan, Head of Global Marketing at Diaceutics (Photo: Business Wire)

DXRX integrates a pipeline of global diagnostic testing data into one secure platform providing access to transparent, real-time reporting on diagnostic utilization at a local level across multiple therapeutic areas.

Early collaborations between pharma, labs and diagnostic companies are live on the platform’s marketplace with 38 Laboratories and Diagnostic Companies onboarded from across EU, Asia and the US. These collaborations are designed to improve test standardization, reimbursement, regulatory support and External Quality Assessment (EQA). Collaborators today include Synlab, PathGroup (US), SRL Diagnostics (Asia), Fundación Jimenez Díaz, The Royal Marsden NHS Foundation Trust, Istituto Nazionale Tumori Regina Elena Roma and Diatech Pharmacogenetics (EU). Two global pharmaceutical clients are also piloting the technology.

The platform enables pharma clients to monitor and enhance test quality at local level to increase return on investment across multiple brands, and leverage a broad network of local partnership opportunities to implement best-in-class testing for their precision medicine portfolios. DXRX also enables clients to outsource the end-to-end diagnostic development and commercialization process from biomarker discovery to in-market test availability in order to reduce time to market for new therapies.

Furthermore, DXRX also provides users access to a global expert advisory panel of key opinion leaders from the areas of oncology, including lung cancer research and colorectal research; pathology, including tissue pathology and uropathology; molecular diagnostics; digital image analysis; telemedicine and informatics; external quality assessment (EQA); and FDA-expertise.

The end-to-end service offering provided by DXRX is enabled by a growing network of industry leading service providers in 51 countries. They cover precision medicine diagnostics to deliver implementation services such as test standardization, reimbursement, regulatory support and External Quality Assessment (EQA). Recent partnerships include Histocyte Laboratories, Targos Molecular Pathology, EMQN CIC, CPQA-ACP, NordiQC and UKNEQAS ICC & ISH.

An

Read more

UK lab joins global network to compare coronavirus vaccine candidates

LONDON (Reuters) – A second British laboratory is joining a global lab network to assess data from potential coronavirus vaccines, set up by a major non-profit health emergencies group to establish the effectiveness of different vaccine candidates.

Earlier this month, the Coalition for Epidemic Preparedness Innovations (CEPI) set up the network, allowing scientists and drugmakers to compare vaccines and speed up selection of the most effective shots.

Britain’s Medicines and Healthcare products Regulatory Agency said on Tuesday the National Institute for Biological Standards and Control (NIBSC) was joining the scheme, and had received funding from CEPI to develop an international standard for the COVID-19 antibody.

That means the NIBSC will produce a sample of antibody with a defined amount of biological activity that can be used by regulators and vaccine makers to calibrate their tests.

“This is an important initiative providing a service to vaccine developers globally and permits accurate evaluation of candidate vaccines for this pandemic,” Dr Mark Page, who is leading the work at NIBSC, said.

Public Health England is also involved in the CEPI scheme.

Hundreds of potential coronavirus vaccines are in various stages of development around the world, with shots developed in Russia and China already being deployed before full efficacy trials have been done, and front-runners from Pfizer <PFE.N>, Moderna <MRNA.O> and AstraZeneca <AZN.L> likely to have final-stage trial results before year-end.

CEPI itself is co-funding nine of the vaccines in development, including candidates from Moderna, AstraZeneca, Novavax <NVAX.O> and CureVac.

(Reporting by Alistair Smout; Editing by Mark Potter)

Source Article

Read more